New combo therapy targets advanced lung cancer after relapse
Disease control
Completed
This study tested a combination of two drugs—pembrolizumab (Keytruda) and Imprime PGG—in 35 people with advanced non-small cell lung cancer whose disease had worsened after initial treatment. The goal was to find a safe dose and see if the combination could slow cancer growth. Th…
Phase: PHASE1, PHASE2 • Sponsor: Lawrence Feldman, MD • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC